Key statistics
52-week range
| Open | 14.20 |
|---|---|
| High | 14.20 |
| Low | 14.20 |
| Bid | 14.40 |
| Offer | 14.60 |
| Previous close | 14.20 |
| Average volume | 229.80 |
|---|---|
| Shares outstanding | 184.69m |
| Free float | 182.84m |
| P/E (TTM) | -- |
| Market cap | 3.08bn USD |
| EPS (TTM) | -1.30 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
- Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
- Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
- Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
- Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
- Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
- Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
- Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
- Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
More ▼
